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Report of the Panel on General Issues in Biotechnology ’ 
Chairman Richard Flavell presented the report of the Panel on General Issues in 
Biotechnology. The Panel considered ways in which the CGIAR might advance its mission 
through greater use of biotechnology. With earlier reservations about the potential benefits of 
biotechnology subsiding, the CGIAR must take appropriate action to ensure that it is not left 
behind as new approaches rapidly become possible. At the same time, it must not lose sight of 
the overriding need to retain an appropriate balance in its activities. 
The Panel concluded that there are widespread opportunities to involve the world scientific 
community in the application of biotechnology to the needs of developing countries. The 
CGIAR is in a strong position to act as a catalyst to foster these contributions, while 
progressively strengthening its use of biotechnology as a tool to further its goals and mission. 
The panel recommended the following: 
FOR THE CGIAR 
l to establish a basic policy fi-amework on biosafety and gene deployment so that 
mechanisms are always in place to ensure that the benefits and risks associated 
with the release of transgenic organisms are assessed; 
l to develop a new strategy to align the CGIAR system with others committed to a 
greater understanding of germplasm; foster the evolution of international networks 
for biotechnological research directly associated with the CGIAR mission; and 
ensure that Centers have the capacity to apply their knowledge to the needs of 
client countries; 
l to help bring about a “genome summit” to assure global collaboration among 
representatives of multinational companies, major funding agencies, charitable 
institutions, and other organizations; 
l to expand international networks for biotechnological research in agriculture, 
fisheries, and forestry; 
l to create a central biological service unit to provide professional advice to the 
Centers on the proprietary, biosafety, and gene deployment considerations of their 
projects. 
1 Extract from: “Summaly of Proceedings and Decisions ‘, Mid-Term Meeting 1998, Brasilia, Brazil, 
25-29 May 1998. 
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FOR THE CENTERS 
l to review in-house expertise in genomics and bioinformatics, and in-house 
capacity to assess biotechnology’s potential contributions to their research; 
l to use “duty of care” committees to assess risks, consult clients, and adhere to 
regulatory procedures for biotechnology. 
Consultative Group on International Agricultural Research (CGIAR) 
TECHNICAL ADVISORY COMMITTEE 
Donald L. Winkelmann, Chairman 
15 April 1998 
Dear Mr. Serageldin, 
I have the pleasure of transmitting to you the report of the CGIAR Panel on General 
Issues in Biotechnology. This report, together with TAC’s Commentary on the Panel’s 
findings, responds to the process that began at MTM’97, when the Group decided to create 
two expert panels under the auspices of TAC to assist the Group in formulating policy on 
biotechnology and protection for intellectual property, as well as for materials held in trust. 
The Panel began its work in September 1997, engaged intensively in electronic 
exchange of ideas, identified key questions on which it sought views from a wide range of 
CGIAR stakeholders and others, and held two meetings. The report reflects the diverse 
opinions derived from broad consultation. As well, TAC solicited comments from a number 
of outside experts. The report and solicited comments were considered at TAC 74, with one 
panel member in attendance. 
The Panel saw its primary role as assessing the current and future application of 
molecular genetics and other developments in biotechnology to those aspects of CGIAR work 
that relate to germplasm improvement. 
The Panel’s recommendations include a strong role for the CGIAR in genomics, i.e., 
developing and supplying molecular biological information, pertaining to its key crops, pests, 
pathogens, and livestock of importance to the poor. As a part of this, the Panel recommends 
that CGIAR be instrumental in a “Genome Summit”, take the lead in an expanded network 
approach to biotechnological research, and review its in-house expertise in relation to the 
preceding initiatives and to its broader research mission. 
. I . . . 
Mr. Ismail Serageldin 
CGIAR Chair 
World Bank 
1818 H Street, NW 
Washington, DC 20433 
USA 
355 E. Palace Avenue, Santa Fe, NM 87501 (l-505) 988-1284 FAX: (l-505) 988-1285 
tacwink@newmexico.com 
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As well, the Panel recommends a policy framework on biosafety and gene 
deployment, a Center-based “duty of care” committee to support the effort on biosafety, and 
the creation of a CGIAR Biotechnology Service Unit. The “duty of care” committee, in 
particular, has several novel aspects, which are treated in the Report. 
The Panel concludes that “there are widespread opportunities for the greater 
involvement of the world scientific community to assist in the application of biotechnology to 
the needs of developing countries. The CGIAR is in a strong position to act as a catalyst to 
foster these contributions, while progressively strengthening its own role as a significant user 
of biotechnology to further the aims of its mission.” 
TAC welcomes this report from the Panel and is pleased to pass it on to you and to the 
Group. The Committee thanks the Panel’s distinguished members for their valuable 
contribution to our better understanding of the vital issues in a fast-moving field. I trust that 
the report will provide you and the Group with information and counsel needed for making 
the policy decisions confronting the CGIAR. 
Sincerely yours, 
Donald L. Winkelmann 
TAC Chair 
TAC COMMENTARY ON THE REPORT OF THE CGIAR PANEL ON 
GENERAL ISSUES IN BIOTECHNOLOGY 
TAC is grateful to Dr. Richard Flavell, Panel Chair, and to the Members of the Panel on 
General Issues in Biotechnology for a concise and thought-provoking report that brings out 
the clear perception of biotechnology as a key instrument for genetic improvement. TAC 
concurs with the Panel that were the term “biotechnology” further defined, more useful 
discussion of the topic would result . TAC noted that the Panel gave strong emphasis to 
genomics and bio-informatics while recognizing the CGIAR strength in germplasm 
collections, knowledge of the mandate crops, collaborative arrangements, testing sites, and 
partnership with NARS. The Panel highlighted the potential role that the CGIAR Centres can 
play in serving the poor as foci on genomic information pertaining to crops, livestock, trees, 
fish, insect pests and pathogens. 
TAC reiterates that the CGIAR’s use of molecular genetics and other biotechnological 
techniques should be strategically grounded in its responsibility as trustee for the genetic 
materials being held. The fulfillment of these trust responsibilities should be clearly linked to 
its mission and to the entire range of stakeholders that the System serves. This establishes the 
moral, ethical and rational foundation for a mandate to fully utilize all appropriate scientific 
tools in serving CGIAR’s ultimate beneficiaries. 
The Committee endorses in general the views set out by the Panel and urges the CGIAR 
Members to carefully consider the report as a whole as it contains many useful 
recommendations and perceptions. TAC endorses in general the recommendations of the 
Panel and offers the following comments to supplement the Panel’s work. 
The Panel, for a variety of reasons, decided to concentrate its study on the applications of 
biotechnology for germplasm improvement. TAC recognizes that the Centres currently, and 
increasingly, will use molecular genetic tools for a broad range of purposes. So, while TAC 
recognizes the current advantage of the Panel’s concentration on germplasm improvement, 
the ultimate scope of work of the System’s work will be in terms of its mission and the 
opportunities through molecular science. Any policy and network activity should therefore 
be able to accommodate a more comprehensive use of molecular genetics. Like the Panel, 
TAC also considers it expedient that the CGIAR Centres have sufficient capabilities to 
interact effectively with others engaged in biotechnology in order to be able to incorporate 
and make the best use of molecular genetics and emerging technologies. 
The Committee notes that the Panel has recommended that the CGIAR be instrumental in 
bringing about the “Genome Summit”. TAC interprets this to be a Summit at a policy and 
administrative level rather than at a scientific level. If so, then TAC wonders whether there 
are other sponsors who could play a facilitating role, with the CGIAR participating where it 
can best serve. 
TAC endorses the recommendation on biotechnology networks as a practical mechanism to 
strengthen information flows. If the Group endorses the recommendation, it is TAC’s view 
that the Centres should be requested to propose models for organization (the Panel describes 
one model), Centre roles, and mechanisms for implementation, e.g., for coordination. 
. . . 
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TAC recognizes that biotechnology is becoming increasingly important as a tool for genetic 
improvement and that the CGIAR Centres need to have in-house capabilities to make best use 
of these new genetic tools. The Committee would like to stress, however, that the Centres 
must ensure that germplasm conservation and improvement programmes continue to receive 
adequate attention, and that, as the Panel recommends, biotechnology and molecular genetics 
should be integrated with these programmes both in terms of planning and funding. 
Finally TAC notes that while the Panel did not focus on biosafety issues but referred to the 
Report of the World Bank Panel on transgenic crops, “Bio-engineering of Crops”, by Kendall 
a al., the Panel has strongly advocated the implementation of “Duty of Care” Committees 
whose task would include the assurance that appropriate safeguards are being met. TAC is 
impressed with the role that such Committees could play. 
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SUMMARY AND RECOMMENDATIONS 
Background 
Following a decision at its mid-term meeting in May 1997, the CGIAR appointed two expert 
panels to advise on the way forward in biotechnology, one focusing on general issues and the 
other on legal aspects. The two panels were designed to work in liaison, three members 
being common to both panels. Accordingly, while fully recognizing the importance of 
proprietary and legal issues for the CGIAR System, the Panel on General Issues has not 
included them in this report. 
Introduction 
The CGIAR mission statement emphasizes the alleviation of poverty and the protection of 
natural resources for sustainable food security. Within these broad aims, the CGIAR makes 
its contributions largely, but not exclusively, through improved technology that increases 
productivity while conserving biodiversity, land and water. It is dependent for its success on 
close collaboration with national research systems in the developing countries. 
The CGIAR Centres have progressively invested in biotechnology and applied its tools to 
their work in areas such as germplasm improvement. However, recent developments, 
especially rapid advances in the molecular characterization of genes, have given new impetus 
to the case for expanding CGIAR investment in selected biotechnological approaches 
(Section 1.1). 
It is against this background that the Panel has prepared its report and recommendations. 
Biotechnology and the CGIAR Mission 
The term “biotechnology” is commonly used in a very broad and general way to mean the 
application of biological discoveries to the development of new products. Concerns about 
some aspects, however, make it essential for assessments to be made, and strategies defined, 
in relation to specific applications. The Panel considers that the CGIAR System should avoid 
using the term “biotechnology” when the aspect in question can be described with greater 
precision using other terms (Section 2.1.). 
Many aspects of biotechnology that are important for the CGIAR mission are based on the 
identification, construction and deployment of genes. The pace and scale of gene discovery, 
characterization and manipulation have been greatly increased in recent years, leading to 
significant decreases in the cost of the operations involved. All phases of genome research 
are interconnected by sophisticated bioinformatics and database capabilities. As a result, the 
future holds the promise of new approaches to germplasm conservation, analysis and 
improvement that combine information on hundreds of thousands of genes with a broadly 
applicable transformation strategy. It is reasonable to infer that any organization committed 
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to these tasks must exploit the new opportunities to be efficient, competitive and viable in the 
future. It is this vision that the Panel wishes to commend to the CGIAR (Section 2.2). 
Nonetheless, the Panel re-emphasizes the view, frequently expressed by others, that retaining 
a balanced approach within the total CGIAR research portfolio will be an essential pre- 
requisite for further progress. Any expansion of biotechnology by the Centres will be an 
evolutionary process that will proceed at different rates, depending on the organism, the 
nature of the problems and the available infra-structure (Section 2.3). 
The CGIAR currently allocates more than 20% of its resources to germplasm improvement 
and conservation and has agreed that this proportion will be somewhat increased in future. 
The links between germplasm improvement and the broader CGIAR mission have been 
firmly established. Consequently, the Panel has seen its primary role as assessing the current 
and future application of molecular genetics to those aspects of CGIAR work that relate to 
germplasm improvement. In doing so, however, the Panel does not discount the value of 
biotechnology to other areas of research relevant to the CGIAR mission (Section 2.4). 
Future Strategy 
A new strategy is required to harness the skills of public and private sector research capacity 
on a global basis, to contribute to the CGIAR mission. The Panel considers it unrealistic to 
suppose that the Centres could undertake, by themselves, the desired research on the scale 
required to meet the future needs of their work (Section 3.1). 
In the Panel’s view, the CGIAR should regard the Centres as major foci for molecular 
biological information pertaining to the key crops, pests, pathogens and livestock that are 
important for the poor. The Centres are likely to remain appropriate places to assay and 
improve germplasm for the properties required to serve their clients and to assist in 
identifying the genes associated with particular traits. They should therefore build 
partnerships and networks with key laboratories and databases to ensure that the new 
knowledge is generated and applied. Nonetheless, biotechnology should always be seen as a 
means of facilitating problem-solving research, rather than as a force affecting its direction 
(Section 3.1). 
It will also remain essential to take into account concerns about the potential risks associated 
with the release of transgenic organisms. The Panel recommends that the CGTAR establishes 
a policy framework on biosafety and gene deployment such that mechanisms are always in 
place to ensure that the benefits and risks associated with the release of transgenic organisms 
are assessed and that the regional and national regulations and priorities are fully observed 
(Section 3.2.1). 
Regarding new approaches, the Panel recommends that the CGIAR should develop a new 
strategy that would include three different, but interrelated, types of activity. One would be 
designed to position the CGIAR System alongside others committed to a greater 
understanding of gerrnplasm. Another would foster the evolution of international networks 
for biotechnological research on problems directly associated with the CGIAR mission, while 
a third would be internal and designed to ensure that Centres have the capacity to apply the 
increasing pool of knowledge to meet the needs of their client countries (Section 3.2.1). 
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Implementation 
The Panel recommends that the CGIAR should be instrumental in bringing about a “Genome 
Summit” involving representatives of multinational companies, major funding agencies, 
charitable institutions and other organizations, at the highest level. The forum created would 
bring together existing genome initiatives, stimulate collaboration, raise the profile of the 
CGIAR mission and bring more information into the public domain (Section 3.2.2). 
The Panel also recommends an expanded networking approach to biotechnological research 
for development in agriculture, fisheries and forestry, in which the Centres would participate 
together with public and private sector organizations throughout the world. Such an initiative 
would require, as a minimum, a new fund, a broadly based steering committee and a 
secretariat. The basic philosophy would be to harness and augment the resources already 
being applied to biotechnology in these areas through collaborative and networking 
approaches. Expert groups would be established to award grants and fellowships on a 
competitive basis and reinforce the Centres’ own activities in building networks (Section 
32.3). 
The Panel recommends that the Centres review their in-house expertise in relation to the 
proposed new strategy. Each Centre would need to review its expertise in genomics and 
bioinformatics, as well as its capacity for assessing, more widely, the potential contributions 
of biotechnology to its research programmes. Strategies for the greater use of 
biotechnological approaches should give appropriate weight to in-house contributions as well 
as to external, collaborative and contractual approaches. Senior staff skills in business 
management and related matters might need strengthening and similar skills would be 
desirable at board level. Centres would also need to review their advisory and training roles 
in biotechnology and related matters and build their capacities accordingly (Section 3.2.4). 
The Panel considers that procedures for evaluating the potential role of transgenics in any 
new product, and for assessing the associated benefits and risks, should be conducted within 
an agreed CGIAR policy framework, on a case-by-case basis. Such procedures should take 
into account the findings of relevant research, including that at the farmer level, and should 
recognize the views of the client countries (Section 3.2.4). 
The Panel recommends that each Centre should have an independent committee exercising a 
“duty of care” to make sure that, for each product, benefits and risks are assessed, clients 
consulted and regulatory procedures strictly adhered to (Section 3.2.4). 
In the Panel’s view, biotechnology should not be treated separately for purposes of planning, 
funding or assessment, either by the Centres or by TAC, but should be fully integrated into 
the broader programmes to which it relates (Section 3.2.5). 
To assist the Centres to expand their work in biotechnology, the Panel recommends the 
creation of a central CGIAR Biotechnology Service Unit capable of giving professional 
advice to the Centres on the proprietary, biosafety and gene deployment considerations of 
their project proposals. It could also help the Centres in their negotiations with potential 
collaborators (Section 3.2.5). 
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Conclusion 
The Panel concludes that there are widespread opportunities for the greater involvement of 
the world scientific community to assist in the application of biotechnology to the needs of 
developing countries. The CGIAR is in a strong position to act as a catalyst to foster these 
contributions, while progressively strengthening its own role as a significant user of 
biotechnology to further the aims of its mission (Section 4). 
1. INTRODUCTION 
1.1 Background 
The CGIAR mission statement emphasizes the alleviation of poverty and the protection of 
natural resources for sustainable food security. Within these broad aims, the CGIAR makes 
its contributions largely, but not exclusively, through improved technology that increases 
productivity while conserving biodiversity, land and water. It is dependent for its success on 
close collaboration with national research systems in the developing countries. 
The CGIAR Centres have progressively invested in biotechnology and applied its tools to 
their work in furthering the CGIAR mission. However, recent developments, especially rapid 
advances in the molecular characterization of genes and genetic variation, have given new 
impetus to the case for greater use of selected applications of biotechnology. It was against 
this background that the CGIAR decided to look in depth at its future strategy on 
biotechnology and related activities. 
The adequacy of its investment in biotechnology was discussed at the Mid-Term Meeting in 
May, 1997 and again in October at ICW97. Several documents provided background 
information and analyses for these discussions. This report does not attempt to summarize 
these documents nor the proceeding of the two meetings. For ease of reference, however, a 
few of the salient points are recapitulated from three of these papers in the following 
paragraphs. 
“A Report on the Highlights of a Stakeholders Consultation”, convened in April 1997 
concluded that the CGIAR was under-investing in biotechnology and conveyed the following 
“messages”: 
l recognizing the potentials of biotechnology as an added tool, the CGIAR should 
proceed with efforts to enhance its capacity for biotechnology research with a special 
emphasis on such technologies as molecular markers and a strong link to breeding, 
farming systems at the smallholder level and ecological considerations, 
l investment in biotechnology research will need to be increased by a significant amount, 
a multiple of the current allocation, 
l stronger partnerships and collaboration are required within the CGIAR System as well 
as between CGIAR Centres and others engaged in biotechnology research, 
l the CGIAR should position itself to ensure that advances in biotechnology can be 
harnessed for the benefit of the poor and for the protection of the environment; it should 
vigorously promote public awareness of the context in which biotechnology programs 
are carried out. 
A background paper compiled by the CGIAR Private Sector Committee under the title: 
“Strengthening CGIAR-Private Sector Partnerships in Biotechnology”, came (inter a&z) to 
the following conclusions. 
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l At a minimum, Centres need the capacity to acce.s,s knowledge and evaluate its potential 
usefulness for their own or their partners’ research. 
l Centres need the capacity to use knowledge obtained from the outside and build on it 
for their own purposes. 
l The Centres’ in-house capacity in biotechnology is important, but without a strong co- 
operative research dimension this capacity is not likely to lead to rapid learning and 
innovation. 
Views from a small-farmer perspective were portrayed in a paper by the Chairman of the 
CGIAR-NGO Committee entitled: “The CGIAR and Biotechnology: Can the Renewal Keep 
Promise of a Research Agenda for the Rural Poor”. The paper drew attention to the 
importance of maintaining the CGIAR research effort on the agro-ecological aspects of crop 
productivity. He outlined the potential contributions of biotechnology to alleviating the 
problems of resource-poor farmers, the limitations of technology promoted by the private 
sector and the risks inherent in the release of transgenic organisms. He also emphasized the 
role of participatory research at the farmer level in developing new agricultural technology 
and improved varieties. 
As a consequence of the discussions generated by these and other inputs at the mid-term 
meeting in May 1997, two expert panels were appointed to advise on the way forward in 
biotechnology, one focusing on general issues and the other on legal aspects. The two panels 
were designed to work in liaison, three members being common to both panels. Accordingly, 
while fully recognizing the importance of proprietary and legal issues for the CGIAR System, 
the Panel on General Issues has not included them in this report. 
Terms of reference, Panel membership and an outline of the programme of work are given in 
Annex I. 
1.2 Consultation 
Before meeting to consider its recommendations, the Panel consulted widely among 
stakeholders and others. In addition, Panel members contacted a range of individuals by 
telephone. The questions posed are listed in Annex II, together with a summary of the salient 
points made and a list of those who responded. The Panel is conscious that scientists in the 
developing countries, as well as NGOs, are under-represented in the list. No attempt was 
made to include farmer organizations in the survey. 
2. BIOTECHNOLOGY AND THE CGIAR MISSION 
2.1 Biotechnology, Bioethics and Biosafety 
The term “biotechnology” is frequently used in a very broad and general way to mean the 
application of biological discoveries to the development of new products. The Panel 
considers it essential that assessments are made, and strategies defined, in relation to 
individual areas of biotechnology and that the CGIAR promotes and defends its position on 
the basis of specific scientific applications, not in terms of “biotechnology” in its generic 
sense. 
This distinction is particularly important because some areas of biotechnology are 
controversial, such as the release of transgenic organisms, whereas others are not, such as the 
use of molecular techniques for the assessment of germplasm in the laboratory. Hence, the 
use of only the generic term by the CGIAR in debates, public awareness programmes and 
discussions with stakeholders is likely to be unhelpful, can be confusing and should be 
avoided. 
The Panel has not discussed in detail those aspects of biotechnology that relate to bioethics, 
biosafety, or gene deployment, but recognizes that the CGIAR needs to develop and observe 
a code of conduct for the application of biotechnology that is explicit, transparent and widely 
publicized. The Panel notes that the CGIAR is giving attention to bioethics through a 
committee established for that purpose. The Panel considers that the CGIAR and the Centres 
should develop formal procedures for deriving regionally and locally acceptable biosafety 
and gene deployment protocols, in consultation with the countries concerned (see also 
Section 3.2.4). 
2.2 Developments and Prospects in Genetics 
Germplasm analysis and improvement, as well as the development of many diagnostic 
techniques and vaccines, are based upon genetic variation, inheritance patterns and the 
association of desired characteristics with genetic determinants. The convergence and 
massive scale-up of the strategies and techniques of molecular biology and genetics are 
underpinning unparalleled increases in precision and efficiency in this work. Two principal 
subfields are discernible: (a) the characterization of gene and genome structure by DNA 
sequencing and associated activities, such as the development of molecular markers for every 
chromosomal region and, (b) the characterization of gene function, gene regulation and the 
control of complex traits, through the use of novel approaches. 
All phases of genome research today are critically dependent upon, and interconnected by, 
sophisticated bioinformatics and database capabilities. As a result of these developments, the 
pace of gene discovery, characterization and manipulation has been vastly accelerated. 
Current estimates indicate that the entire Arabidopsis genome will be sequenced by the year 
2000. Moreover, because of the commonality of the genetic code and conservation or 
convergence of structures to perform similar tasks across all biological kingdoms, the pool of 
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interpretable genomic information is expanding at an exponential rate, as the complete 
genomes of many organisms are being sequenced, analyzed and deposited in databases. 
These molecular genetic analyses are being carried out in many public sector laboratories 
around the world, in large multinational corporations and also in small specialist companies 
which do contract research for other organizations. As the scale of these operations increases 
so the cost of the information decreases. It is therefore projected that the molecular genetic 
analysis of any genome will become a routine, highly automated procedure within the next 
two decades. 
Translating this genomic knowledge into improved germplasm requires the creation of new 
gene combinations, whether achieved through classical plant breeding or by introduction of 
genes in the laboratory. Improvements in this transformation technology are also being 
developed at a rapid rate and for many crops including cereals, such as rice, wheat and maize. 
Transformation technology is already being widely used for the introduction of single-genes 
to enhance, for example, disease-resistance. 
Thus, the future holds the promise of combining information on hundreds of thousands of 
variant genes from many species with a generic, broadly-applicable transformation strategy. 
As a consequence, it is reasonable to infer that any organization committed to germplasm 
conservation, analysis and improvement must gain and exploit these innovations to be 
efficient, competitive and viable in the future. It is this vision that the Panel wishes to 
commend to the CGIAR. 
2.3 The Over-riding Need for a Balanced Approach 
The development and dissemination of the improved technology through which the CGIAR 
seeks to further its mission is undertaken in a holistic context that encompasses all the 
relevant natural and social sciences. Any expansion of molecular genetic approaches within 
the CGIAR must constantly be viewed in this context and the Panel re-emphasizes the view, 
frequently expressed by others, that retaining a balanced approach within the total CGIAR 
research portfolio will be an essential pre-requisite for further progress. The Panel also 
concurs with the view, expressed in the report to the World Bank of the Panel on Transgenic 
Crops, that any increased investment in new agricultural technology must be accompanied by 
significant investment in ecological and sociological research to ensure support for safe and 
sustainable food production. 
The Panel recognizes that any expansion of molecular genetics and transgenics by the 
CGIAR will be an evolutionary process that will proceed at different rates, depending on the 
organism, the nature of the problem and the available infrastructure. In some instances there 
will be a shortage of trained personnel or inadequate infrastructure in terms of the supply, on 
a regular and reliable basis, of the necessary materials and reagents to meet laboratory 
requirements. Equally, in some countries, there may not be adequate facilities for servicing 
and repairing complex equipment. In the Panel’s view, these considerations should not deter 
the CGIAR from putting in place the suggested internal and external structures. It would then 
be possible to expand the selected biotechnological approaches as and when it becomes 
feasible to do so, recognizing that the appropriate balance will vary with each set of 
circumstances. 
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2.4 Relevant Applications of Biotechnology 
Those who responded to the Panel’s survey described many applications of biotechnology 
that would accelerate progress in CGIAR projects, These responses are summarized in 
Annex II (questions 1 and 2). They cover applications related to the productivity of crops, 
livestock and aquatic organisms as well as to problems related to ecology, environmental 
conservation and germplasm banks. Some of these applications and the transgenic crops 
currently adopted into agriculture are elaborated in Annex III and Annex IV for the reader 
who has no specialist knowledge of biotechnology. 
The CGIAR currently allocates more than 20% of its resources to germplasm improvement 
and conservation, and has agreed that this proportion will be somewhat increased in future. 
The links between germplasm improvement and the broader CGIAR mission have already 
been firmly established and summarized in various documents produced by TAC. 
Consequently, the Panel has seen its primary role as assessing the current and future 
application of molecular genetics to those aspects of CGIAR work that relate to germplasm 
improvement. In doing so, the Panel does not in any way discount the value of biotechnology 
to other areas of research that are also relevant to the CGIAR mission. 
Many biological techniques, such as those associated with tissue culture, have been widely 
used for many years. The Panel has not regarded such applications as part of its study, but 
has concentrated on molecular and biochemical aspects. Within these applications, the Panel 
has given greatest attention to the application of molecular genetics to crop improvement, 
recognizing that many of the topics discussed are also relevant to trees, livestock and fish 
2.5 The Application of Molecular Genetics to Crop Improvement 
The Panel concludes that there are widespread opportunities for assisting developing 
countries through the application of molecular genetics to crop improvement. The Panel is 
aware, however, of the concerns that are commonly expressed about some of these 
applications, whether soundly based or not. For example, there is strong opposition from 
those who see biotechnology as a vehicle for acquiring unjustified proprietary rights, while 
practicing plant breeders have been critical of the cost-effectiveness of some of the 
techniques on offer. In addition, criticisms have arisen because of unwarranted and 
unfulfilled claims of what is achievable through biotechnology within a given time frame. 
Although the Panel recognizes such concerns, it notes that there will be many opportunities to 
take advantage of those aspects of biotechnology for which the benefits greatly outweigh the 
risks. There will also be applications to which the concerns do not apply, such as marker 
assisted selection. Such techniques, used for screening breeders’ material, have no adverse 
environmental implications and plant breeders’ criticisms are increasingly being met by the 
dramatic reductions in cost and the increased scale on which they can be applied. Moreover, 
any proprietary rights attached to the techniques do not necessarily threaten the release, as 
public goods, of the improved germplasm derived from them. 
The development of these techniques is dependent on genome mapping. The Panel is 
concerned that investment in genomics by the CGIAR is very small compared with similar 
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investment by the private sector. Although the private sector is motivated partly by the rush 
to acquire proprietary rights, the Panel considers that the CGIAR is already being left behind 
in this work, as related to future requirements for the improvement of its mandated crops, as 
well as for the maintenance and use of its germplasm banks (see Annex III). 
Many of the concerns surrounding biotechnology are more specifically related to genetic 
engineering and the release of transgenic organisms than to other applications. The Panel 
recognizes the need both for more research aimed at assessing the benefits and risks of such 
releases and for adequate precautions to overcome any risks identified. Nevertheless, the 
potential benefits to be derived from transgenic plants, especially to resource-poor farmers, 
cannot be ignored. 
In routine plant breeding aimed at the needs of the small farmer, the transfer of desirable 
genes from gene-bank accessions to important cultivars within the same species can be 
accelerated by marker assisted selection and genetic engineering. Similarly, through 
transformation, desirable traits that cannot be found within the same species can be 
transferred from sources outside it. Such traits include complex characters under polygenic 
control, such as the components of yield. 
The Panel discusses the implications of these and similar developments in later sections of 
this report, insofar as they relate to the need for a revised CGIAR strategy. 
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3. REQUIREMENTS FOR THE FUTURE 
3.1 The Need for New Approaches 
New approaches are required that harness the skills of public and private sector research 
capacity on a global basis, to contribute to the common purpose. Centre involvement could 
be seen as providing hubs for a networking approach in which each commodity Centre 
continues its role in germplasm enhancement, expands its role as the repository of 
information on its mandated crops and assists in the transfer of biotechnology to its partners 
in the developing world. 
Taking into account the strengths and weaknesses of the multitude of organizations and 
institutions involved in biotechnological research, the Panel considers it unrealistic to 
suppose that the Centres could undertake, by themselves, the desired research on the scale 
required to meet the future needs of their work. The cost of developing adequate in-house 
capacity would be prohibitive and would inevitably detract from other vital activities. These 
considerations apply whether the required facilities were to be developed at each Centre, or at 
one or more Centres as shared facilities. 
Given some of the projected changes in research approaches, the Panel considers that there 
will remain a major long-term role for the Centres to apply state-of-the-art research, 
knowledge and technology relating to problems in germplasm improvement. In the Panel’s 
view, the CGIAR should regard the Centres as major foci for molecular biological 
information pertaining to the key crops, pests, pathogens, livestock and fish that are important 
for the poor. 
To fulfill such a role, the Centres would need to be major players at the leading international 
tables concerned with policies on the acquisition and utilization of information on molecular 
genetics for the analysis, conservation and enhancement of germplasm. They would also 
need to develop capabilities in bioinformatics to gather, use and disseminate the information 
acquired in these areas. 
The primary information on commercial crop genomes is being generated in public and 
private sector laboratories on a global basis. Much of it is directly or indirectly useful to the 
Centres. The CGIAR needs to negotiate the means, and establish the mechanisms, to have 
direct access to present and future information. Additional mechanisms will be required to 
acquire information on the orphan crops within the CGIAR mission. Many laboratories and 
especially the large multinational companies are well provided with both human and 
technical resources to generate molecular characterizations of complex genomes. The 
CGIAR should use these resources and seek to take advantage of such facilities to further its 
own mission. 
However, the Centres are likely to remain the appropriate places to assay and improve 
germplasm for the properties required to serve their clients and to assist in identifying the 
genes associated with particular traits. They should therefore build partnerships and 
networks with key laboratories and databases to ensure that relevant new knowledge is 
generated and applied. 
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Similar considerations apply to the use of molecular genetics in Centre programmes in areas 
of research other than germplasm improvement, such as applications to research on agro- 
ecosystems. Full integration of relevant molecular genetics into each programme or project 
would continue to be essential. Molecular genetics should be seen as a tool for facilitating 
problem-solving research, rather than as a force affecting its direction. 
3.2 A New CGIAR Strategy 
3.2.1 The Basic Framework 
For the CGIAR to remain abreast of developments in biotechnology and to take full 
advantage of them to further its mission, new structures and administrative arrangements will 
be needed. It will also remain essential to take into account concerns about the potential risks 
associated with the entry of transgenic crops into agriculture and food chains. Consequently, 
there is an urgent need to work towards universally acceptable biosafety and gene 
deployment protocols and to promote the research needed to refine and implement them. 
The Panel recommends that the CGIAR establishes a policy framework on biosafety and 
gene deployment such that mechanisms are always in place to ensure that the benefits and 
risks associated with the release of transgenic organisms are assessed and that the regional 
and national regulations and priorities are fully observed. 
Regarding new approaches, the Panel has not attempted to be prescriptive, but has discussed 
the principles involved. The Panel recommends that the CGIAR should develop a new 
strategy that would include three different, but interrelated, types of activity. One would be 
designed to position the CGIAR alongside others committed to a greater understanding of 
germplasm. Another would foster the evolution of international networks for 
biotechnological research on problems directly associated with the CGIAR mission, while a 
third would be internal and designed to ensure that Centres have the capacity to apply the 
increasing pool of knowledge to meet the needs of their client countries. Although these 
three types of activity would be separate in conception, there would be close links between 
them. 
3.2.2 Global Collaboration 
The rapidly advancing fields of genomics and bioinformatics, while becoming extremely 
competitive areas for the private sector, also present new opportunities for the CGIAR 
System. The Panel considers it vital that the mission of the CGIAR, the work of its Centres 
and the needs of the developing countries are more widely recognized at all levels in the 
relevant scientific structures. These already include initiatives such as the Human Genome 
Project, the International Arabidopsis Genome Programme, the International Rice Genome 
Programme and the National Genome Initiative of the USA (see Annex V). 
The Panel therefore recommends that the CGIAR should be instrumental in bringing about a 
“Genome Summit” involving representatives of multinational companies, major funding 
agencies, charitable institutions and other organizations, at the highest level. The forum 
created would establish the broad goals and standards required for greater understanding of 
the genomes of the principal organisms on which the planet depends and thus strengthen the 
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role of the CGIAR in making such information more readily available to the developing 
countries. 
In the first instance, such a forum need not be distracted by issues of intellectual property, 
since these are fast changing issues that can be resolved through specific negotiations. The 
aims of the “genome summit” would be to: 
l bring together existing genome initiatives into a common perspective; 
l define the global needs, goals and standards; 
l define policies that will stimulate collaboration at all levels within the relevant 
scientific communities; and 
l ensure that the CGIAR’s mission and activities are recognized as of crucial importance 
in the field of genomics. 
The Panel sees such a summit as a means of pulling potentially large amounts of additional 
resources and information, relevant to the CGIAR, into the genomics arena, thus advancing 
the CGIAR mission and benefiting the other collaborators. Ideally, much of the information 
stemming from such a global effort would be seen as international public goods from which 
all countries, all institutions and all people could eventually benefit. To get such a 
programme off the ground would require vision and universal goodwill. The Panel considers 
that the CGIAR could have an important role in meeting this challenge. 
3.2.3 International Networks for Biotechnological Research 
The Panel also recommends an expanded networking approach to biotechnological research 
for development in agriculture, fisheries and forestry. Such an initiative would require, as a 
minimum, a new fund, a broadly based steering committee and a secretariat. The basic 
philosophy would be to harness and augment the resources already being applied to 
biotechnology in these areas through collaborative and networking approaches. Expert 
groups would be established to award grants and fellowships on a competitive basis and 
reinforce the Centres’ own activities in building networks. 
Some of its activities might well build on the experience already gained from initiatives such 
as the International Rice Biotechnology Programme sponsored by the Rockefeller Foundation 
(see Annex V). Although networks of this type need to be backed by a fund to provide seed 
money, the value of the collaborative work far exceeds the cost of the central input. 
Participation in this type of network creates a group of scientists who develop a feeling of 
common ownership that leads them to contribute in ways that far exceed their formal 
commitment. The networking approach also has an important training function and can 
incorporate numerous ways of drawing on existing skills and facilities. 
The association of the Centres with all such activities would be similar to the association of 
IRRI, CIAT and WARDA with the Rockefeller Foundation’s programme. The Centres 
would contribute to the work of the networks and draw on their products. They would also 
be competitors for grants alongside other applicants and would help to identify candidates 
from national programmes for fellowships, sabbatical leave and other similar arrangements. 
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If this idea finds favour, detailed thought would have to be given to whether or not it would 
be feasible to promote and assist the multiplicity of different networks implied through one 
administrative agency. The central steering committee and secretariat would have the tasks 
of helping to find donors for a central fund for the award of grants and fellowships, as well as 
for the support of individual projects. The Panel’s view is that to establish a semi- 
independent central mechanism for these functions would be preferable to imposing these 
tasks on Centre staff. 
3.2.4 Centre Roles and Capacities 
The Panel recommends that each Centre should review its in-house expertise in relation to 
the proposed new strategy. 
Centres involved in germplasm improvement will require sufficient expertise to monitor 
progress within the relevant global genomics community, participate in the overall effort and 
make decisions on how information and resources on molecular genetics should be used. 
Internal skills in bioinformatics (see Annex III) will become increasingly important for the 
effective use of genomic data generated within the informal global networking system. 
Existing networks in genomics consist of scientists and institutions, both public and private, 
with common interests in acquiring and interpreting information. They are typically 
supported by bioinformatics through the WWW and databases, and are funded from a variety 
of sources. These networks and their constituent scientists and institutions will be the 
engines of discovery for the CGIAR needs in genomics. Guiding their outputs towards the 
needs of the poor will be an important role for the Centres. 
In addition to reviewing its skills in genomics and bioinformatics, each Centre would also 
need to review its capacity for assessing, more widely, the potential contributions of 
biotechnology to its research projects and to re-consider its strategies for exploiting new 
discoveries. Such strategies should give appropriate weight to in-house contributions as well 
as to external, collaborative and contractual approaches. 
For example, a Centre could contract an industrial company to map the molecular diversity 
within 20,000 accessions of its germplasm collection using 1,000 markers, or perform the 
molecular diagnostics work in its marker-assisted breeding programmes using state-of-the-art 
efficiencies present nowhere else in the world. Leading scientists at advanced research 
institutes could be given “joint appointments” or be formally affiliated to the Centres to help 
ensure a long-term commitment. Exchange of resources and personnel could be formalized 
Where proprietary rights are involved and the material or technique is not freely available for 
use in developing countries, the Centres should consider promoting research to circumvent 
such restrictions. However, there will also be many aspects of biotechnology of importance 
to the CGIAR mission that will remain of little interest to profit-making organizations in the 
short and medium terms. It is these aspects, in particular, that could be developed as 
international public goods. 
Senior staff skills in business management and related matters might well need strengthening 
and similar skills would be desirable at board level. Centres would also need to review their 
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advisory and training roles in biotechnology and related matters and build their capacities 
accordingly. 
The Centres should also be prepared to undertake research to examine the potential risks in 
cases where there would be significant benefits in releasing transgenic organisms. The Panel 
considers that procedures for evaluating the potential role of transgenics, and for assessing 
the associated benefits and risks, should be conducted within the agreed CGIAR policy 
framework (see Section 3.1), on a case-by-case basis. Such procedures should take into 
account the findings of relevant research, including that at the farmer level, and should 
recognize the concerns of the client countries. 
The Panel recommends that each Centre should have an independent committee exercising a 
“duty of care” to make sure that, for each product, benefits and risks are assessed, clients 
consulted and regulatory procedures strictly adhered to. 
The scope for greater inter-Centre collaboration in the use and exchange of biotechnological 
experience and information was mentioned in several of the returns to the Panel’s 
questionnaire. Various suggestions were made for networking and other collaborative 
activities. The Panel strongly endorses the principles described and considers that the 
possibilities should be explored further, perhaps through an inter-Centre meeting on 
biotechnology. (The Panel understands that the last such meeting was held in 1989.) 
3.2.5 Administrative Implications for the CGIAR 
Within the CGIAR administrative structure, the Panel sees TAC as encompassing 
biotechnology in its routine consideration of Centre programmes. Hence, it will need to draw 
on appropriate expertise from within or outside its regular membership. In the Panel’s view, 
however, biotechnology should not be treated separately for purposes of planning, funding or 
assessment, either by the Centres or by TAC, but should be fully integrated into the broader 
programmes to which it relates. 
To assist the Centres to expand their work in biotechnology, the Panel recommends the 
creation of a central CGIAR Biotechnology Service Unit capable of giving professional 
advice to the Centres on the proprietary, biosafety and gene deployment considerations of 
their project proposals. It could also help the Centres in their negotiations with potential 
collaborators. 
The Panel sees this Central Service Unit as commenting on all proposed Centre projects that 
involve aspects of biotechnology. The existence of such a unit would automatically help in 
sharing experience and information among the Centres and the countries they serve. In the 
context of the more general dissemination of information on policies and practices, the Panel 
sees scope for creating a Web site for information on bioethics, biosafety and gene 
deployment. An appropriate organization might be commissioned to run such a site. 
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4. CONCLUSIONS 
The Panel has considered ways in which the CGIAR might advance its mission through 
greater use of the tools of biotechnology. Earlier reservations about the potential benefits of 
biotechnology are now being overtaken by the increased rate of discovery of new knowledge, 
the development of new techniques and the scale on which they can be applied. The Panel 
concludes that the CGIAR must take appropriate action to ensure that it is not left behind in 
the new approaches rapidly becoming possible. At the same time it must not lose sight of the 
overriding need to retain an appropriate balance in the totality of its activities. 
The Panel also concludes that there are widespread opportunities for the greater involvement 
of the world scientific community to assist in the application of biotechnology to the needs of 
the developing countries. The CGIAR is in a strong position to act as a catalyst to foster 
these contributions, while progressively strengthening its own role as a significant user of 
biotechnology to further the aims of its mission. 
ACKNOWLEDGEMENTS 
The Panel is most grateful to those who responded to the ten questions; to those who 
provided information for Annex III; to the Rockefeller Foundation for hosting the meeting in 
New York; and to Jeni Fox of the John Innes Centre, Norwich, UK, for secretarial and 
administrative 
ANNEX I 
TERMS OF REFERENCE, PROGRAMME OF WORK 
AND PANEL MEMBERSHIP 
1. Terms of Reference 
The Panel on General Issues in Biotechnology was given the following terms of reference: 
The Panel will: 
1. Identify issues of major concern to the CGIAR that will facilitate positioning the 
CGIAR in the global agricultural research system. 
2. Provide advice and guidelines on immediate or long-term needs with respect to: 
comparative advantage analysis; risk management; strategic alliances; and strategy and 
resources. 
3. Prepare a draft strategy on biotechnology for the CGIAR, taking into consideration 
needs of the Centres and stakeholders, identifying options for the strategic involvement 
of the CGIAR in the use of biotechnological approaches to solving problems relative to 
its mission. 
4. Prepare a report and recommendations to be presented to TAC for commentary and for 
consideration by the Group at its mid-term meeting scheduled for May 25-29, 1998. 
2. Programme of Work 
An initial meeting of the Panel was held in Singapore on 21 September 1997. Six Panel 
members (Flavell, Dryden, Quail, Toenniessen, Uchimiya and Zhang) were able to attend, 
together with Tim Roberts (Chairman of the panel on proprietary issues). Dr Rota (CIAT) 
and Dr Bennett (IRRI) joined this group for part of the meeting. 
Discussion at the meeting led to drawing up a framework for the study and formulating ten 
questions that were used for a survey conducted by mail and telephone early in 1998. The 
initial responses to these ten questions provided background information for the second 
Panel meeting held in New York on 26 - 27 January. This meeting was attended by nine 
Panel members (Flavell, Dryden, Padmanaban, Toenniessen, Goodman, ole-MoiYoi, Seitzer, 
Uchimiya and, through a conference telephone, Altieri). The Panel Secretary also attended. 
The meeting identified the issues to be included in the report and reached consensus on the 
main conclusions. Thereafter, the work was continued through correspondence, mainly by e- 
mail. 
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ANNEX II 
SALIENT POINTS FROM RESPONSES 
TO THE 
PANEL’S TEN QUESTIONS 
1. Introduction 
Before meeting to discuss its recommendations, the Panel (through its Chairman) invited 
responses to ten questions. The questions were distributed to a wide range of CGIAR 
stakeholders and others. The Panel is conscious that the replies do not necessarily constitute 
a fully representative sample of all stakeholders. Nonetheless, reasonably wide coverage was 
achieved using names suggested by the Chairman of TAC, Panel members and others. In 
addition, Panel members consulted widely by teIephone on the same questions. 
This Annex summarises the responses. They have not been analysed quantitatively, but an 
attempt has been made to reflect the diversity of opinions expressed, as well as to indicate the 
main areas of common ground. 
2. General Impressions 
Perceptions of the appropriate level of future CGIAR investment in biotechnology differ 
widely. Many are strongly supportive of biotechnology; others remain unconvinced that 
there should be increased investment in this area. A few are strongly opposed to any 
additional investment in biotechnology, while several make the point that the CGIAR should 
stick to its problem-solving, bottom-up philosophy and should not apply a top-down 
(technology-push) approach. Some emphasize the importance of agro-ecological approaches 
backed by participatory research at the farmer level. Mention is also made of the practical 
difficulties of rapid expansion in biotechnology, such as staffing, training, infrastructure, 
supplies and services. 
Many, unfamiliar with the details of the technology, tended to relate “biotechnology” to the 
generation of transgenic organisms and the control of their ownership by patents. Those 
more familiar with the details emphasized the opportunities for applying the new analytical 
techniques to germplasm improvement and other ventures. 
Against this background, the word “caution” featured in various different contexts but 
especially in those related to biosafety and other risks. At the same time there was general 
agreement that the CGIAR should position itself so as not to miss emerging opportunities in 
biotechnology, which are seen as extending well beyond genetic improvement. Some see 
increased emphasis on biotechnology as essential for the survival of the Centres as credible 
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research institutes. Some donors support increased investment by the CGIAR in 
biotechnology; others await guidance from the two Panels. 
3. The Ten Questions 
1. What developments are likely to emerge in biotechnology from the advanced public 
institutions and major companies, over the next IO years, that should be exploited to ful@l the 
CGIAR mission? 
Developments identified in the responses to this question are many and varied. Genomic 
characterisation, and its application to identifying desirable genes, is generally regarded as a 
key area, whether stated explicitly or by implication. Marker-aided selection and 
transformation feature strongly as providing new ways of enhancing desirable characteristics 
or of inserting special traits into well adapted genotypes. Among lists of desirable traits, the 
most commonly cited are resistance to biotic and abiotic stresses, as well as the quality of 
harvested products. Gene promoters allowing their expression in particular tissues also 
receive attention. Several responses mention the potential value of apomixis and induced 
male sterility in the final production of improved crop varieties, while both apomixis and 
clonal production feature for trees. Diagnostic techniques are mentioned in a wide range of 
contexts. 
CIFOR and IIMI do not see a compelling need to become heavily involved in biotechnology 
as they both have natural resources mandates. ICRAF explains the potential for 
domestication in tree species and the wide differences in the nature of the problems 
encountered compared with those of arable crops. IPGRI has special aims related to 
germplasm banks; ICLARM sets out its vision of the use of biotechnology in relation to 
aquatic organisms; and ILRI covers applications to livestock improvement and disease 
control (see Annex III for amplification of these aspects). 
2. What biotechnological developments are client countries seeking and expecting? 
Developing countries wish to take advantage of any developments in biotechnology that they 
perceive as beneficial, such as cheap and reliable selection techniques based on molecular 
markers. Some are already active in the main areas of research involved and others are 
moving in that direction. 
The role of Centres in forming bridges for the transfer of biotechnology and assisting with 
capacity building, is a recurring theme. There is general recognition that developing 
countries vary in the extent to which they are currently geared up to incorporate 
biotechnology into their research programmes. The need for training, information services 
and advice (especially on biosafety and proprietary rights) is commonly cited. 
3. Who should decide what biotechnology products areproduced by CGIAR initiatives? 
Some considered existing processes of strategic planning and priority setting to be adequate 
for integrating biotechnology into current programmes. Some argue that all CGIAR 
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stakeholders, including donors, should be involved in decision-making or that decisions 
should be made by an independent panel. There seems to be a majority view, however, that 
decisions should be de-centralised. Centres should operate within a broad policy framework 
determined by the CGIAR and then be free to make their own decisions based on a bottom-up 
approach in which the developing countries have full participation. There is also a view that 
market forces will influence what the Centres do. Central (CGIAR) scrutiny would be 
through the processes already in place (budgets, medium-term plans, external reviews, etc.). 
There is a view that TAC should find ways of remaining in closer touch with biotechnology. 
4. What are the implications for client countries, NGOs and consumers of the recommended 
adoption of biotechnology by the CGIAR, and what part should IARCs play in facilitating the 
acceptance of agreed biotechnology products? 
Implications for client countries are broadly seen as positive. However, several responses 
emphasize the importance of establishing recognized biosafety mechanisms in developing 
countries and the need for appropriate delivery systems for the products of biotechnology. 
There is a view that this may not be possible without full participation of the private sector. 
Client countries will need to invest in laboratory facilities and personnel if they are to make 
full use of biotechnology in their own research programmes and to enable them to collaborate 
actively with Centres and others. 
An important role of the CGIAR is seen as catalytic, as a provider of information and 
advisory services to create greater awareness of both the benefits and the risks. CGIAR 
Centres could help client countries and NGOs to keep fully in touch with the scientific, legal 
and biosafety aspects. 
5. What biotechnology partnership models should be developed between IARCs, NARSs, 
NGOs and industries to deliver the mission of the CGIAR more effectively and efficiently? 
There is strong support for partnerships and involvement of the private sector both in research 
collaboration and in delivery systems. The replies tend to be in terms of broad 
generalizations, with recognition that models cannot be determined in advance and are better 
developed on a case-by-case basis. There is strong support for networking approaches. One 
reply suggests central co-ordination with, perhaps, a new Centre. 
6. What kinds of partnerships, networks and business agreements need to be developed and 
adopted to ensure the best technolo,ay can be exploited by IARCs? 
Many different arrangements are described in the responses. There is general recognition of 
the need for Centres to have access to the latest developments in biotechnology and hence the 
need to form alliances (preferably of mutual benefit) with other organizations in both the 
public and private sectors. Attention is drawn to the opportunities for contracting some of the 
work to outside organisations, rather than the Centres attempting to do all of it themselves. 
Several respondents mention the need for some form of central capacity within the CGIAR to 
give advice on the various types of alliance. 
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One specific idea (CIMMYT) is for a CGIAR-sponsored information network that could 
establish a database for molecular data relating to accessions in the various germplasm banks. 
Greater and more frequent interchange of ideas and experience among Centres also features 
in some responses. 
7. Khat investments and management changes would be required in the IARCs to enable 
them to implement the desired changes as new opportunities emerge from biotechnology? 
Responses vary. Some see no need for a “big bang” but regard the Centres as being on an 
evolutionary pathway that will gradually incorporate more biotechnology as appropriate. 
Others see the need for major new investments in personnel and equipment. Special-project 
funding is regarded by many as inappropriate for much of the work. The importance, at 
senior staff and board level, of skills in business management, proprietary rights and related 
matters is mentioned by many. 
8. What are the implications for the IARCs for senior appointments, staff cohorts, training 
and turnover lfthe recommended levels of biotechnology are adopted by the CGIAR 
There is general recognition of the need (where not already met) for a member of the senior 
management staff to hold responsibility for monitoring developments in biotechnology and 
guiding Centre strategies and priorities. Most see changes being made through evolutionary 
processes, rather than by a dramatic change. 
IPGRI describes the value of its Honorary Fellows embedded in advanced research 
institutions, an idea that has much in common with other suggestions for ways of drawing 
upon the expertise and facilities of other organisations to help with Centre programmes. 
There was a suggestion, for example, that there might be technology units within universities, 
funded to work explicitly on CGIAR problems. 
9. What will be the best structure, funding mechanisms and management systems for the 
IARCs in the future in order to make best use of biotechnology? 
Current de-centralised structures are, in general, regarded as suitable. Additional skills will 
be required, such as in business management, IPR etc. especially for collaboration with the 
private sector. Some argue that this capacity should be centralised as a CGIAR special unit 
to negotiate with the private sector on behalf of all Centres. Greater inter-Centre 
collaboration is mentioned (including sharing facilities where appropriate) but there is little 
support for a central laboratory serving all Centres. 
There is widespread support for networks in advanced science, involving the best laboratories 
in the world being linked to the Centres. Increased and long-term funding is regarded as 
essential and might be provided through special arrangements involving the World Bank, 
Foundations and other donors. 
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10. What are the risks for the IARCs and the CGIAR in developing germplasm using the 
systems, tools and information of biotechnology and, conversely, in not exploiting 
biotechnology adequately? 
(a) Greater use of biotechnology: Possible distortion of CGIAR priorities. Might be 
perceived as a “technology push”. Exposure to criticism if products are released in countries 
with inadequate biosafety monitoring mechanisms. The consequences of mistakes could be 
severe. Possible loss of public goodwill. Some products might prove difficult to deliver to 
resource-poor farmers. 
(b) No expansion in biotechnology: Loss of valuable opportunities to assist research 
programmes in developing countries and further the CGIAR mission. Loss of scientific and 
funding opportunities. Loss of credibility of the CGIAR as a leading research organisation. 
Private sector ownership of biotechnology and its products would predominate. 
4. List of Those Who Responded 
Amtzen, Professor Charles, Boyce Thompson Institute for Plant Research Inc. (USA) 
Aveldano, Dr. Rodrigo, INIFAP-SARI-I (Mexico) 
Bedbrook, Dr. J., DNA Plant Technology Corporation (USA) 
Bennett, Dr. John, IRRI 
Bennett , Mr Andrew J., Department for International Development (DFID) UK 
Bie, Dr. Stein, ISNAR 
Brader, Dr. Lukas, IITA 
Briggs, Dr. Steve, Pioneer Hi-Bred International Inc. (USA) 
Buchanan, Dr. Alex, Crawford Fund for International Agriculture Research (Australia) 
Biichting, Dr. A., KWS Kleinwanzlebener Saatzucht AG (Germany) 
Carsalade, Mr Hem-i, Food and Agriculture Organization of the UN 
Coffman, Professor W. Ronnie, Director, Cornell Agri. Exp. (USA) 
Dalodom, Dr. Ananta, Department of Agriculture, (Thailand) 
Davis, Dr. Jeremy, International Development Manager, PBIC (UK) 
El-Beltagy, Dr. Adel, ICARDA 
Evans, Dr. David, Zeneca Agrochemicals (UK) 
Fisher, Dr. Ken, International Rice Research Institute (IRRI) 
Fitzhugh, Dr. Hank, ILRI 
Friedrichsen, Dr. J., GTZ (Germany) 
Gowda, Dr. C., ICRXSAT 
Hall, Prof. T., Texas A & M (USA) 
Hardy, Dr. Ralph, Ex DuPont and Ex Boyce Thompson Institute (Canada) 
Hawtin, Dr. Geoffrey, IPGRI 
Hoisington, Dr. Dave, CIMMYT 
Hopper, Mr. David, Ex World Bank and Ex Chair, CGIAR (Canada) 
Izard, Mr. Maurice, Sous-direction du dev. economique et de l’environment (France) 
Jacobsen, Prof. H.J., Universitgt Hannover (Germany) 
James, Dr. Clive, IS&%4 (Cayman Islands) 
Kiirschner, Dr. E., GTZ (Germany) 
Lampe, Dr. K., ex DG IRRI (Germany) 
Lewis, Mr. John V., US Agency for International Development (USA) 
MacGillivray, Mr Iain C., CIDA (Canada) 
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Maeno, Dr. Nobuyoshi, Japan Int. Research for Agri. Sciences (Japan) 
Mazur, Dr. Barbara, DuPont Agricultural Products (USA) 
McCalla, Dr. Alex, Agriculture and Natural Resources, World Bank 
McConnell R., Pioneer Hi-Bred International Inc. (USA) 
McCouch, Prof. Susan, Plant Breeding Department, Cornell University (USA) 
Mellon, Dr. Margaret, Union of Concerned Scientists, Washington (USA) 
Miflin, Professor Ben, Institute of Arable Crops Research (UK) 
Ndiritu, Dr. Cyrus, Kenya Agriculture Research Institute (Kenya) 
Noome, Dr. C., Advanta (USA) 
Nwanze, Dr. Kanayo, WARDA 
Padolina, Dr. W., Dept. of Science & Technology, (Philippines) 
Peacock, Prof. J., CSIRO (Australia) 
Petit, Mr Michael J., The World Bank 
Reeves, Professor’Timothy, CIMMYT 
Robbelen, Prof. G., Universitat Giittingen (Germany) 
Rota, Dr. Willy, CIAT 
Salamini, Professor Francesco, Max-Planck-Institut f?.ir Zuchtungsforschung (Germany) 
Sanchez, Dr. Pedro, ICRAF 
Sayer, Dr. Jeffrey, CIFOR 
Schilde, Prof. L., Universitat Ttibingen (Germany) 
Scobie, Dr. Grant, (with Rota response) CIAT 
Seckler, Dr. David, IIMI 
Seratos-Hemandez, Dr. Jose Antonio, INIFA (Mexico) 
Shegal, Dr. Suri, AgrEvo USA - PGS America (USA) 
Strong, Mr. Maurice, Advisor to the President, World Bank 
Thomstron, Mr. Carl-Gustaf, Director, SIDA, (Sweden) 
Thrupp, Dr. Lori Ann, World Resources Institute (USA) 
Toenniessen, Dr. Gary, The Rockefeller Foundation (USA) 
Trigo, Dr. Eduardo, President, Fundacion ArgenINTA (Argentina) 
Vasil, Dr. Indra, University of Florida (USA) 
Virgin, Dr. Ivar, Stockholm Environment Institute (Sweden) 
von Montagu, Professor Marc, Laboratorium Genetika (Belgium) 
Waffula, Dr. James, Kenya Agricultural Research Institute (Kenya) 
Weimin, Mr. Yang, Asian Development Bank (Philippines) 
Wenzel, Prof. Dr. G., Universitat Weihenstephan (Germany) 
Wettstein, Professor Diter von, Washington State University (USA) 
Williams, Dr. Meryl, ICLARM 
Winkel, Mr Klaus, Danish Int. Dev. Assistance, Ministry of Foreign Affairs (Denmark) 
Wolpers, Dr. K.H., GTZ (Germany) 
Zandstra, Dr. Hubert, CIP 
ANNEX III 
APPLICATIONS OF BIOTECHNOLOGY RELEVANT TO 
THE CGIAR MISSION 
1. Introduction 
Some donors suggested that the Panel’s report should not only analyze the issues for 
decision-makers, but should also be informative for the layman. This Annex has been 
prepared with the second of these requests in mind but makes no attempt to cover the whole 
spectrum of possible applications. It elaborates some of the statements made elsewhere in the 
report and provides a few specific examples of relevant biotechnological applications. 
Some of those who responded to the Panel’s questions on present and future contributions of 
biotechnology (see Annex II), did so primarily in relation to improved products (such as 
drought tolerant plants), rather than to new techniques that can be used in their development 
(such as marker assisted selection). The Panel has not attempted to forecast in detail what 
improved products are likely to emerge as a result of greater CGIAR investment in 
biotechnology. Rather, it has focused on the technology that will increasingly become 
available for accelerating the development of improved products, and on the steps that will be 
needed for such technology to become readily available for use by the Centres and the 
developing countries they serve. 
2. Genomics, Synteny and Bioinformatics 
Molecular biology is providing new insights into the structure of the genome at an 
exponential rate of growth. Such studies and the knowledge they generate are broadly 
referred to as “genomics”. 
The term “synteny” was originally applied to genes presumed, from the results of marker 
analysis, to occur on the same chromosome. More recently, however, the term has been used 
in the same sense as “collinearity of genetic maps” to mean the similarity in the order of 
genes that occurs along chromosome segments over a wide range of organisms. 
The insights provided by genomics have been likened to the understanding of hieroglyphics 
provided by studies of the Rosetta stone. Thus, knowledge of the mouse genome, for 
example, provides valuable information on the human genome, while more closely related 
organisms, such as rice and wheat, show remarkable similarities in gene organisation, 
sequence and function. It follows that, because of genomic synteny, there is enormous 
potential for sharing and exchanging information across a wide range of organisations and 
individuals working on different organisms. The computerised accumulation and 
interpretation of this knowledge has acquired the new name of “bioinformatics”. 
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3. The Relevance of Genomics 
Just as classical genetics provides indirect knowledge of whether genes are linked or 
inherited independently, so genomics provides direct information on the sequence, function, 
activity, position and grouping of genes on the chromosome. The techniques of molecular 
biology and genetics that have evolved since the dawn of the recombinant DNA era have 
given rise to systematic, high throughput, whole-genome sequencing and associated 
activities, such as the development of molecular markers for detecting the presence of genes 
or groups of genes, directly or by genetic linkage. 
The future will see substantial reductions in cost and increased speed of large-scale 
sequencing through automation, robotics and, eventually, microarray chip-based techniques. 
These offer the prospect of capturing vast amounts of genomic information on a single chip 
and using it to determine how the activity of each and every gene varies with the environment 
and genetic background. 
Once the complete catalogue of all genes in a plant has been determined (year 2000) then it 
will be relatively simple to find the equivalent gene in any plant. Similarly, the sequence of 
the human genome will lead to relatively rapid identification of genes in the principal farm 
animals. Once a gene has been shown to play a role in controlling a trait in one species, it 
will be straightfonvard to investigate the equivalent trait in another species. The 
development of such activities is already accelerating and the Centres need to remain aware 
of the new opportunities that are constantly emerging. 
4. Gene Transfer 
Improvements in the technology required to design genes, insert them into plant cells and 
regenerate transformed, fertile plants, continue to be made, even for the more difficult crops 
such as wheat and maize. However, many of the orphan crops of critical importance to the 
CGIAR remain to be transformed efficiently and some general problems associated with the 
expression of inserted genes remain to be solved. Nevertheless, the recent commercial 
introduction of transgenic crops gives grounds for supposing that such problems will 
eventually be solved. 
Although arguments have been raised against the release of transgenic crops, in many cases 
there is no reason why, ultimately, they should present a greater hazard to the environment 
than varieties produced as a result of classical hybridisation techniques. Perceived dangers, 
such as the use of antibiotic markers to select transformed cells, will be overcome by 
improved methods already in the pipeline. 
The extent to which transgenic crops are now entering agriculture is illustrated by the 
following table extracted from ISAAA Briefs (1997), and by Annex IV. 
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Traits already Commercialised in Field Trials, and under Development for Selected 
Crops, 1997 
Crop Traits already commercialised Traits in Field Trials/Development 
Canola I. Herbicide Tolerance 
2. Hybrid technology 
3. Hybrid technology and herbicide tolerance 
4. High lauric acid 
I. Improved disease resistance 
2. Other oil modifications 
Corn I. Control of Corn-Borer 
2. Herbicide tolerance 
3. Insect protected/herbicide tolerance 
4. Hybrid technology 
5. Hybrid/herbicide tolerance 
1. Control of Asian Corn-Borer 
2. Control of Corn Rootwonn 
3. Disease resistance 
4. Higher starch content 
5. Modified starch content 
6. High lysine 
7. Improved protein 
8. Resistance to storage grain pests 
9. Apomixis 
cotton I. Bollworm control with single genes 
2. Herbicide resistance 
3. Insect protected/herbicide tolerance 
I. Bollworm control with multiple 
genes 
2. Control of Boll Weevil 
3. Improved fibrektaple quality 
4. Disease resistance 
Potato I. Resistance to Colorado Beetle 1. Resistance to Colorado Beetle + 
virus 
2. Multiple Virus resistance 
(PVX, PVY, PLRV) 
3. Fungal disease resistance 
4. Higher starch/solids 
5. Resistance to potato weevil/ 
storage pests 
Rice I. Resistance to bacterial blight 
2. Resistance to rice-borers 
3. Fungal disease resistance 
4. Improved hybrid technology 
5. Resistance to storage pests 
6. Herbicide tolerance 
Soybean 1. Herbicide tolerance 
2. High oleic acid 
1. Modified oil 
2. Insect resistance 
3. Virus resistance 
Tomato I. Delayed/Improved ripening I. Virus resistance 
2. Insect resistance 
3. Disease resistance 
4. Quality/high solids 
Vegetables 
& Fruits 
I. Virus resistance I. Insect resistance 
2. Delayed ripening 
Source: Clive James, 1997, Global Status of Transgenic Crops, ISAAA Briefs 2 
A few transgenic farm animals have been produced but it will be some time before this 
technology is suitable for widespread use. 
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5. Applications to Germplasm Improvement 
Knowledge of the genome enables molecular markers to be developed. Breeders make 
progress through selection among varying genotypes often based, during the early stages of 
selection, primarily on phenotypic differences. At best, they can only estimate the genotypic 
variation, using the results of replicated progeny tests. However, molecular markers permit 
direct assessment of genotypic variation and they can be used to detect the presence of both 
single genes and polygenic complexes. This applies whether the genes are dominant or 
recessive. Moreover they can be used at the juvenile stage, such as seedlings, to detect genes 
that are not expressed until maturity. Provided the marker techniques are reliable and can be 
applied on a large enough scale, they provide valuable tools for the plant breeder and 
accelerate selection processes. They are also extremely helpful in characterising germplasm 
collections (see below). 
Numerous examples of how the tools of biotechnology are being used to improve crop 
varieties, have been given above and in Annex IV. In addition the following have been 
selected simply to give a few examples of the types of approach that are now possible across 
a wide range of crops and problems. 
(a) Recognition of Valuable Genes and Marker Assisted Selection 
The rapid break-down of single gene resistance through changes in the pathogen is well 
known. Its consequences are loss of yield, which can be avoided only through the use 
fungicides that may not be accessible to the poor. In the past, some progress has been made 
towards achieving “durable” resistance by breeding two or more resistance genes into the 
same variety, through prolonged schemes of crossing and selection. However, biotechnology 
gives new impetus to such approaches. Insights into the genomics of both host and pathogen 
are providing greater understanding of host-pathogen interactions which, together with 
techniques such as marker assisted selection, are providing new strategies for building 
multigenic resistance into crop plants. 
‘For example, recent work on rice blast disease by CIAT scientists and their collaborators has 
focused on genes resistant to “lineages” of pathotypes rather than on those resistant to 
specific isolates, as revealed by traditional pathotype analysis. Biotechnology has provided 
ways of defining the genetic organization and distribution of diversity in the pathogen and 
has facilitated the incorporation of appropriate resistance genes into breeding lines. Such a 
strategy for attacking a formerly intractable problem could have wide application to other 
crops and diseases. 
(b) Production of Transgenics 
Although rice is the world’s most important food crop, it is not a good source of vitamins or 
iron. Vitamin A deficiency is a serious problem in many rice dependent poor populations, 
with children who are weaned on rice gruel at particularly high risk. The carotenoid 
biosynthetic pathway is now well understood and genes for all steps have been cloned from 
plants and microbes. It is now possible to manipulate the pathway in rice through genetic 
engineering with the objective of increasing the beta carotene content of the grain. Similar 
approaches could be applied to other crops in which the harvested product is deficient in 
vitamin A. 
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Another example of nutritional improvement relates to the iron. Several different strategies 
are being pursued for increasing the bio-available iron in rice. The most advanced involves 
adding the gene for a protein such as fenitin which accumulates iron and makes it available. 
It has been shown that rice seeds transformed with a ferritin gene from soybean store up to 
three times more iron than normal seeds. Other strategies focus on phytate, a derivative of 
phytic acid, which binds iron in a non bio-available form. It may well be possible to reduce 
the phytate content in the grain or to introduce the gene for phytase which breaks down the 
phytate and releases iron in an available form. 
(c) Rhizomania-resistant Sugarbeet 
Although sugar beet does not feature strongly in the agriculture of developing countries, 
recent work on Rhizomania provides a good example of the application of molecular 
techniques to breeding for resistance to a disease in which expression is strongly influenced 
by the environment. 
Rhizomania (root madness or bearded root) is a destructive disease of sugar beet (Beta 
vulgaris L.) caused by the beet necrotic yellow vein virus whose vector is a soil borne fungus. 
Rhizomania is widespread in the temperate regions of Europe and Asia and occurs in USA. 
The disease causes losses as high as 80% in some parts of Europe and reductions of 20-50% 
in sugar yield and juice purity are common in infested fields. Viruliferous resting spores of 
the vector have been reported to survive in uncultivated fields for as long as 15 years. No 
chemical control of the virus is possible. 
Breeding for resistance to Rhizomania began in the eighties when a single source of tolerance 
to the virus was discovered. Tolerance was weakly expressed and the trait was found to be 
inherited through many genes, The level of tolerance was difficult to maintain when 
introducing it into the then elite lines. Early recognition of the environmental hazards of 
using fungicides and the then intractable nature of breeding for high levels of tolerance led 
Kleinwanzlebener Saatzucht (KWS) to mount a two-pronged effort, one through 
conventional breeding methods and the other through molecular approaches, to search for a 
means to introduce Rhizomania resistance into sugarbeet. Both methods have since yielded 
results. 
New sources with higher levels of tolerance found later were used successfully to introduce, 
through backcrossing, Rhizomania tolerance into elite varieties. These varieties suffer no 
significant damage when the crop is attacked by the virus. However, they do not inhibit virus 
replication. With the development of molecular techniques, investigations showed that plants 
expressing viral coat protein genes interfere with the multiplication of this virus. A viral gene 
that synthesizes the beet necrotic yellow vein virus coat protein and inhibits its replication has 
been successfully incorporated into sugarbeet. Transgenic sugarbeet now offers cross 
protection against Rhizomania. These transformants compare well with the results of 
classically bred sugarbeet hybrids for plant growth and yield. Early tests have shown that 
hybrids that combine transgenic resistance and classical tolerance perform better than current 
classically bred Rhizomania-resistant varieties under heavy infection. 
The basis for Rhizomania-resistance breeding at KWS was and continues to be the 
identification of genetic sources of high level resistance that can be inherited easily, an 
efficient selection for resistance which includes both screening methods and marker-aided 
selection, and short breeding cycles. Through the use of various kinds of molecular markers 
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closely linked to the Rhizomania resistance genes, screening for the presence of the gene and 
fingerprinting parental genotypes is achieved. Conventional breeding techniques combined 
with biotechnological ones offer an efficient means to produce Rhizomania-resistant varieties 
that have high yield and sugar content. 
Biosafety aspects related to the release of transgenic sugarbeet have been investigated by 
independent agencies. No negative effects have been reported. 
6. Applications to Germplasm Banks 
Genomic knowledge is fundamental to the classification and utilisation of germplasm 
collections. Without such knowledge, germplasm banks have been likened to “stamp 
collections” which spend most of their time in unopened albums. Over the next few years, 
there will be major technical advances that will facilitate the automated screening of 
chromosomal segments in large numbers of samples. 
Molecular genetics also opens up entirely new avenues for the transfer of desirable genes 
from germplasm accessions to advanced cultivars, through transformation and marker 
assisted selection. Recent work has shown that, as well as providing genes for resistance to 
pests and diseases, primitive ancestors of crop plants also contain genes, not present in 
advanced cultivars, that can enhance yield and quality. These can be recognised through 
molecular assays. 
In this general context, IPGRI comments on the rapid technical advances in gene transfer, in- 
vitro conservation and diversity analysis. Key technologies include cryopreservation and 
artificial seed development, as well as a range of molecular genetic methods. Further 
advances in sequencing technologies and in chip-based analyses are likely to be of 
considerable significance in the analysis of diversity and in determining useful traits. Other 
important applications relate to the rationalisation of germplasm management, such as the 
identification of duplicate samples within and between collections, as well as the 
development of core collections. 
7. Applications to Agroforestry 
The following outline is based on information supplied by ICRAF. 
An important aspect of agroforestry is the domestication of tree species, in contrast to the 
unsustainable exploitation that has typified their use in the past. Some 2,500 tree species are 
known to be used in agroforestry systems in one way or another, making it essential to focus 
on a few carefully chosen species. The large number of species involved is only one of 
several ways in which the problems of agroforestry differ from those of crop productivity. 
ICRAF does not see biotechnology as being amongst its top priorities in the immediate future 
but recognises the potential for biotechnology to contribute to certain specific problems. 
For example, most trees are outbreeding and heterozygous and also have a prolonged 
generation time. The most useful techniques in the foreseeable future are likely to be 
molecular markers for selection at the juvenile stage, methods for the large-scale 
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multiplication of selected trees, such as by cloning or apomixis, and techniques for inducing 
flowering to shorten the generation cycle. 
8. Applications to Livestock Improvement 
ILRI points out that, in considering the future exploitation of biotechnology for livestock 
research and development, it is important to note the major differences between livestock and 
plants. Many aspects of biotechnology that are relevant to crop improvement also apply to 
livestock improvement. These include genome analysis, molecular genetics and marker 
assisted selection. These techniques are even more beneficial in livestock improvement, 
however, because the generation time for livestock is generally longer than in crops, the 
number of offspring per generation is relatively small and the consequent cost of breeding 
programmes is high. 
Other important applications to livestock improvement include a wide range of diagnostic 
techniques, vaccines and new drug technologies, as well as transfection/transgenics for 
livestock, forages and rumen micro-organisms. 
9. Applications to Aquatic Organisms 
The following outline of applications of biotechnology to aquatic organisms has been 
condensed from information provided by ICLARM. 
ICLARM draws attention to the growing importance of molecular markers for biodiversity 
research, genome mapping and trait selection in fish and other aquatic organisms. 
International groups are already collaborating on genetic maps of tilapia and common carp 
(of most direct relevance to ICLARM) as well as maps for salmonids, catfish, zebrafish and 
pufferfish. Maps for commercially important invertebrate species including shrimp and 
oysters are being initiated. 
ICLARM is not currently working on transgenesis, but several other institutes and companies 
in the fisheries and aquaculture sectors are conducting such research on various species 
including tilapia. It is anticipated that there will be an increase in the number of species and 
strains into which genes are introgressed, and the number of gene constructs available for 
transgenesis (governing biological functions in addition to growth) will also be increased. 
Transgenesis may become a cost effective means of enhancing indigenous species important 
to one or a few countries and not covered by international breeding efforts. 
Sex manipulation (e.g. the production of all male populations of fish, especially tilapia) is 
also an active area of research, designed to avoid the detrimental production effects of early 
maturation and cessation of growth. In carp species, however, all-female populations are 
required and are being requested by developing countries. It is also anticipated that sex 
reversal will be used more widely in breeding programmes to increase the speed of 
production of inbred lines. Haploid fish will be important for similar reasons. 
A wide range of diagnostic techniques is being developed for applications such as disease 
diagnosis, sexing of juvenile fish and for assessing progeny relationships in large populations 
of fish raised together to reduce environment-specific variations in production. Other 
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techniques include tissue culture, or other manipulations of embryos or embryonic cells, for 
the isolation of viruses, bacteria and fungi pathogenic to fish. 
10. Additional Information 
To supplement the information in this Annex, the reader might wish to refer to some of the 
earlier reports and publications that cover relevant biotechnology in the context of developing 
countries. Among these, a paper by Gary Toenniessen (1995) and two reports edited by 
Gabrielle Persley (1990) are particularly informative in the context of this report. Other 
reports are mentioned in the introduction to the main text. 
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ANNEX IV 
EXECUTIVE SUMMARY OF GLOBAL STATUS OF 
TRANSGENIC CROPS IN 1997 
C. James 
Excerpts from ISAAA Briefs &1997 
Transgenic Field Trials 19864997 
During the twelve years period 1986 to 1997, approximately 25,000 transgenic crop field 
trials were conducted globally on more than 60 crops with 10 traits in 45 countries. Of this a 
total of 25,000 tests, 15,000 field trials (60 percent) were conducted during the first ten year 
period, 1986 to 1995, and 10,000 (40 percent) in the last two year period, 19961997. 
Seventy-two percent of all the transgenic crop field trials were conducted in the USA and 
Canada followed in descending order by Europe, Latin America and Asia, with the few 
conducted in Africa limited to South Africa. The most frequent crops featuring in transgenic 
crop field trials during the period were corn, tomato, soybean, canola, potato, and cotton. 
The most frequent traits were herbicide tolerance, insect resistance, product quality and virus 
resistance. 
It is noteworthy that 25,000 transgenic crop trials were conducted without encountering any 
significant constraints that did not lend themselves for successful and responsible 
management during experimentation at the field level. This reflects well on regulators and 
experimenters who worked together effectively to conduct and manage 25,000 trials in a 
responsible manner and ensured that the results were communicated in a transparent mode 
and open for scrutiny and discussion by the scientific community and the lay public. The 
continued sharing of information from transgenic crop trials and their performance during 
commercial deployment is important and will contribute to a better understanding of 
transgenic crops and enhance public acceptance of products that can make a critical 
contribution to future global food security. As of year-end 1997,48 transgenic crop products, 
involving 12 crops and 6 traits, were approved for commercialization in at least one country 
by 22 proprietors of technology, of which 20 were private sector corporations. 
1996 Commercialized Transgenic Crops 
The People’s Republic of China was the first country to commercialize transgenics in the 
early 1990s with the introduction of virus resistant tobacco, which was later followed by a 
virus resistant tomato. In 1994, Calgene obtained the first approval in the USA to 
commercialize a genetically modified food product, when the company marketed its Flavr 
SavrTM delayed ripening tomato. By 1996, approximately 2.8 million hectares of 7 principal 
transgenic crops were grown commercially on a significant area in the following 6 countries, 
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listed in descending order of area planted with transgenics: USA, China, Canada, Argentina, 
Australia and Mexico. 
In 1996, on a global basis, 57 percent of the area of transgenic crop was grown in the 
industrial countries and 43 percent in the developing countries. USA grew most of the 
transgenic crops, equivalent to 1.5 million hectares (51 percent), followed by China, 1.1 
million hectares (39 percent), with Canada and Argentina at the same level of 0.1 million 
hectares (4 percent), and the balance in Australia (1 percent) and Mexico (1 percent). 
In 1996, the principal transgenic crop grown was tobacco which accounted for 35 percent 
(equivalent to 1.0 million hectares) of the global area, followed by cotton (27 percent) on 0.8 
million hectares, and soybean 18 percent (0.5 million hectares); the balance of 20 percent was 
made up of corn (10 percent), canola (5 percent), tomato (4 percent), with less than 1 percent 
of global transgenic area occupied by potatoes. 
By trait, virus resistance accounted for 40 percent of the 1996 acreage of transgenic crops, 
followed by insect resistance, synonymous with insect-protected (37 percent), herbicide 
tolerance (23 percent), with quality traits accounting for less than 1 percent. 
1997 Commercialized Transgenic Crops 
In 1997, the global area of transgenics increased 4.5 fold from 2.8 million hectares in 1996 to 
12.8 million hectares with 7 crops grown in 6 countries, as in 1996, with 48 transgenic crop 
products approved in at least one country. The countries listed in descending order of area of 
transgenic crops were: the USA, with 8.1 million hectares representing 64 percent of the 
global acreage with transgenic crops, China with 1.8 million hectares equivalent to 14 
percent, Argentina with 1.4 million hectares representing 11 percent of global acreage, 
Canada with 1.3 million hectares representing 10 percent of global area and Australia (50,000 
hectares) and Mexico, 30,000 hectares, both representing less than 1 percent of the global 
acreage with transgenic crops. 
On a global basis, the proportion of acreage with transgenic crops grown in industrial 
countries increased from 57 percent in 1996 to 75 percent in 1997, and it decreased 
accordingly in developing countries from 43 percent in 1996 to 25 percent in 1997. The 
largest expansion in area of transgenic crops in 1997 occurred in the USA (6.7 million 
hectares) where the increase was more than fivefold (5.6) the 1996 levels, followed by 
Argentina (1.3 million hectares) where there was a 13 fold increase, and Canada with an 
increase of 1.3 million heck&s, representing a 9.2 fold increase. The USA continued to be 
the principal grower of transgenic crops in 1997 and its share of global acreage planted to 
transgenic crops increased from 5 1 percent in 1996 to 64 percent in 1997, equivalent to 8.1 
million hectares. Whereas China, in 1997, still retained its 1996 ranking as the country with 
the second largest area, its percentage of global acreage of transgenic crops decreased sharply 
from 39 percent in 1996 to 14 percent in 1997. Argentina’s area of transgenic crops 
increased from 4 percent of global area in 1996 to 11 percent in 1997, and similarly Canada 
expanded its share from 4 percent to 10 percent. 
There were also significant changes in the absolute and relative area occupied by the 7 
transgenic crops in 1996 and 1997. Transgenic soybean ranked first in 1997, accounting for 
40 percent of global acreage sown to transgenic crops, and replaced tobacco (13 percent in 
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1997) which was the highest ranking crop in 1996 with 35 percent of the global area. Corn, 
which only ranked fourth in 1996 (10 percent of global area of transgenics) moved up to 
second position in 1997 with 3.2 million hectares, equivalent to 25 percent of the global area 
planted to transgenic crops. The share occupied by transgenic canola increased fi-om 5 
percent in 1996 to 10 percent in 1997, whereas the area of cotton decreased from 27 percent 
to 11 percent, and tomato fell also, from 4 percent to 1 percent. 
The relative areas occupied by the four transgenic traits were also significantly different in 
1996 and 1997. Herbicide tolerance, the third ranking trait in 1996 and occupying 23 percent 
of the area, in 1997 moved to the top ranking position with 54 percent of the global area. 
Insect resistance was fairly stable with 37 percent in 1996 and 31 percent in 1997, with virus 
resistance decreasing sharply from 40 percent in 1996 to 14 percent in 1997; quality traits 
occupied less than 1 percent in both 1996 and 1997. 
Major Changes 1996 to 1997 
Considering the global share of transgenics for the respective countries, crops and traits, the 
major changes between 1996 and 1997 were correlated with the following features: growth in 
area of transgenics between 1996 and 1997 in the industrial countries was significant and 
almost 4 times greater than in developing countries (7.9 million hectares versus 2.0 million 
hectares); soybean and corn contributed 75 percent of the global growth in transgenics 
between 1996 and 1997; herbicide tolerance was responsible for 63 percent (6.2 million 
hectares) of the global growth in transgenics between 1996 and 1997, with insect resistance 
contributing 30 percent and virus resistance only 7 percent. 
The principal phenomena that influenced the change in absolute area of transgenic crops 
between 1996 and 1997 and the relative global share of different countries, crops and traits 
were: firstly, the enormous increase in 1997 of herbicide tolerant soybean in the USA and to 
a lesser extent in Argentina; secondly, the significant increase in 1997 of insect resistant corn 
in North America; and thirdly, the large increase of herbicide tolerant canola in Canada in 
1997. Collectively, these three phenomena resulted in a global acreage in 1997 that was 4.5 
times higher than 1996, and the relative importance of transgenic tobacco and tomato in 
China, which was significant in 1996, decreased markedly in 1997 in a global context. In 
1997, transgenic soybean, corn, cotton and canola represented 86 percent of the global 
transgenic area, of which 75 percent was grown in North America with herbicide tolerant 
soybean being the most dominant transgenic crop followed by insect resistant corn and 
herbicide tolerant canola. 
Estimated Benefits from Transgenic Crops 
More detailed information on the benefits associated with new transgenic crops will be 
available following a comprehensive analysis of 1997 data, when a substantial acreage of 
transgenics was planted globally. An initial assessment of the benefits from transgenic crops 
is reported here. Virus resistant tobacco in China increased leaf yield by 5 to 7 percent and 
resulted in savings of 2 to 3 insecticide applications. Insect resistant Bt cotton in the USA in 
1996 resulted in insecticide savings, with 70 percent of Bt cotton planted in 1996 requiring no 
insecticides to control the targeted insect pest, and an average yield increase of 7 percent, this 
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resulted in a net benefit of about US$ 80 per hectare for a total national benefit of US$ 60 
million for the 730,000 hectares of Bt cotton in the USA in 1996. 
Borer-resistant Bt corn in USA produced an average yield increase of 9 percent in 1996 and 
1997. The benefits from the use of Bt corn on 285,000 hectares in the USA in 1996 were 
estimated at US$ 19 million and US$ 190 million for the 2.8 million hectares of Bt corn 
planted in 1997. About 50 percent of the 32 million hectares corn acreage in the USA, 
equivalent to 16 million hectares have been reported to be infested with European corn borer, 
with an estimated annual loss of US$ 1 .O billion. 
In 1996, in the USA herbicide tolerant soybean resulted in 10 to 40 percent less herbicide 
requirements, improved yield dependability, no carry-over of herbicide residues, more 
flexibility in agronomic management and better control of weeds and soil moisture 
conservation. 
In 1996, in Canada herbicide tolerant canola lowered herbicide requirements, increased yield 
by an average of 9 percent, with no carry-over of herbicide residues, more flexibility in 
agronomic management, and with a higher proportion of Grade #l canola, i.e., 85 percent 
versus 63 percent, as well as better soil and moisture conservation. The benefits to Canada 
from the use of 125,000 hectares of herbicide tolerant canola in 1996 were estimated to be 
Can$ 6.0 million. 
In 1996, in the USA insect resistant Bt potatoes resulted in effective control of Colorado 
beetle, with yield/quality benefits of US$ 34 and additonal insecticide savings of US$ 12, for 
a net benefit of US$ 46 per hectare. This translated to a total benefit of US$ 170,000 for the 
3,650 hectares of Bt potatoes in the USA in 1996. 
Thus, at a national level in the USA in 1996, the total benefits for Bt cotton, corn and potato 
were US$ 80 million, and US$ 190 million for Bt corn alone in 1997. Similarly, at the 
national level the benefits from herbicide tolerant canola in Canada in 1996 were Can$ 6 
million. In general, transgenic crops have been well received in North America, with a very 
high percentage of farmers who planted transgenic crops in 1996 electing to plant them again 
in 1997. Many transgenic products were unavailable to potential growers in North America 
in 1997 because of shortage of transgenic seed supplies, thus reducing the potential area 
planted to transgenic crops. 
The Future - Biotechnology Investments and Global Markets 
Global sales for agricultural biotechnology will continue to be modest compared with 
biotechnology-based pharmaceutical products. In the USA in 1995 revenues from 
agricultural biotechnology were estimated at US$ 0.10 billion with R&D costs of US$ 2.0 
billion, whereas revenue for biotechnology-based pharmaceuticals was US$ 7.0 billion with 
R&D costs of US$ 8.0 billion; in 1996 revenues for agricultural biotechnology products in 
the USA increased to US$ 304 million and to US$ 8.6 billion for biotechnology-based 
pharmaceuticals. 
However, revenue from agri-biotech products is expected to increase significantly in the 
future as expansion of transgenic crops continues and as a shift occurs from the current 
generation of “input” agronomic traits to the next generation of “output” quality traits, which 
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will result in improved and specialized nutritional food and feed products that will satisfy a 
high-value-added market; the recent US$ 1.7 billion joint venture between DuPont and 
Pioneer is probably directed at this market. Biotechnology-driven acquisitions, mergers and 
alliances will continue to prevail in the seed and pesticide industry which has invested US$ 8 
billion in acquisitions in agri-biotechnology alone in the last few years, although the thrust in 
the future will change to vertical integration of food, feed and industrial products, and the 
current focus on genomics will catalyze new alliances. 
The future for transgenic crops looks promisin g, with crop areas in North America likely to 
increase significantly in 1998, deeper market penetration in Latin America and Australia, new 
products in China and the advent of commercial transgenic crops in Europe. The global 
market for transgenic crops is projected to increase from less than US$ 0.5 billion in 1996, to 
a value between US$ 2.0 and US$ 3.0 billion in 2000, and to USS 6.0 billion in 2005, and is 
forecasted to rise to about US$ 20 billion in 2010. During the next decade an increase in 
productivity of 10 to 25 percent from transgenic crops is feasible and realistic and this will be 
a critical and significant contribution to global food security, more nutritious food and feed, 
and to a safer environment. 
ANNEX V 
THE ROCKEFELLER FOUNDATION’S 
INTERNATIONAL PROGRAMME 
ON RICE BIOTECHNOLOGY 
The organization and administration of the Rockefeller Foundation’s International 
Programme on Rice Biotechnology has been discussed by Toenniessen (1995). The 
programme is described as an integrated set of research, training, technology-transfer and 
capacity-building activities. It is structured to produce improved rice varieties that will 
benefit low-income rice producers and consumers in developing countries. The grants and 
fellowships awarded under the Program are designed to contribute to one or more of its 
clearly defined aims. These include the development of biotechnology for application to 
tropical rice, the strengthening of biotechnology capacity in rice-dependent countries, the 
greater understandin g of the consequences of technical changes in agriculture and the 
application of this knowledge to the production of improved seed and other materials used by 
farmers. 
The programme operates within clearly defined policies on proprietary rights and biosafety. 
It is a condition of the award of grants that all materials and technology resulting fi-om 
research supported within the programme should be freely available to all participants for use 
in developing countries. At the same time, grantees are encouraged to pursue intellectual 
property rights on their discoveries to obtain an economic return in developed countries to 
support further research and to maintain a strong bargaining position. 
To help establish biosafety systems that are workable, effective and based on rigorous 
scientific evaluation, the programme includes contributions from professionals from agencies 
and organizations that have experience and responsibilities in these areas. In addition, the 
Foundation helped to establish the Biotechnology Advisory Commission, a unit of the 
Stockholm Environment Institute. The commission is designed to help developing countries 
assess the possible environmental, health and socio-economic effects of proposed 
biotechnology introductions. 
It was recognised from the outset that creating the programme and its associated networking 
activities would be an evolutionary process and require a long-term commitment. From its 
beginnings in 1984, the programme has now clearly demonstrated the value of this approach. 
It has shown how relatively small inputs can act as “leverage” for larger contributions. Those 
who participate in the programme acquire a sense of ownership that induces them to help 
each other and to contribute in ways that far exceed their formal commitment. This long- 
term nature of the programme, with the prospect of renewed grants, has been one essential 
element of success. Another has been the rigorous scientific review of quality and progress 
that has been a feature from the outset. 
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Grants and fellowships are awarded within a semi-competitive framework and, in addition to 
the information they make available, they have also provided valuable training opportunities. 
Some proposals are submitted on the initiative of prospective grantees; others are solicited by 
the programme administrators. Workshops have proved useful in identifying important 
research areas. The programme has had close links with IRRI, CIAT and WARDA, but the 
Centres have not acted as implementing agencies. 
Some of the principles developed in this programme have also been applied to other networks 
and other crops, but there is clearly scope for their wider application. 
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National Plant Genome Initiative 
Executive Summary 
The Need for a National Plant Genome Initiative: Recent scientific advances made 
through our nation’s investments (private and public sector) in studying DNA structure and 
function in humans and model organisms have resulted in a new biological paradigm for 
understanding the traits of organisms. Through the National Plant Genome Initiative (NPGI), 
this paradigm can be extended to improving the useful properties of plants that are important 
to humanity. Solutions to many of our nation’s greatest challenges can be met through the 
application of plant-based technologies. For example, the revitalisation of rural America will 
come from a more robust agricultural sector; reductions in greenhouses gases can be achieved 
from the production of plant biomels for energy; chemically contaminated sites can be 
rehabilitated economically using selected plants; and world-wide malnutrition can be greatly 
reduced through the development of higher yielding and more nutritious crops that can be 
grown on marginal soil. 
The Initiative’s Goais: The long-term goal is to understand the structure and function of 
genes in plants important to agriculture, environmental management energy, and health. 
Reaching this goal will require a sustained commitment from the Federal government 
working in collaboration with other nations and with the private sector. The Initiative’s short- 
term goals, to be achieved over the next five years, focus on building a plant genome research 
infrastructure by: 
l completing the sequencing of the model plant species Arabidopsis; 
l participating in an international effort to sequence rice; 
l developing the biological tools (e.g., physical maps, expressed sequence tags, mutants) to 
study complex plant genomes (e.g., corn, wheat, soybean, cotton); 
l increasing our knowledge of gene structure and function of important plant processes; 
l developing the appropriate data handling and analysis capabilities; and 
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l ensuring this new information will be ‘accessible to the broader community of plant 
biologists (e.g., growers, breeders, physiologists, biotechnologists) and maximising the 
training opportunities that will arise from the Initiative. 
The Initiative’s Operating Principles: 
l The Initiative should be viewed as a long-term project, governed by a plan that will be 
updated periodically. 
l All resources, including data, software, germplasm, and other biological materials should 
be openly accessible to all. 
l The Federal portion of the Initiative should be co-ordinated by a National Science and 
Technology Council interagency working group. 
l All awards should be made on a competitive basis with peer review. 
l Partnerships with the private sector and with other nations are vital for success. 
Funding: To accomplish the five year goals of the NPGI, at least US$ 320 million could be 
used by the Federal government in a targeted manner to leverage existing plant genome 
activities in the public and private sectors. Current estimates of cost could be decreased with 
advances in technology. 
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